Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23471459 | 0.92 | SIGMAR1 (0.43) | SMN1; SMN2KEAP1ALOX15PIK3CDSIGMAR1 | |
| SCHEMBL1308167 | 0.86 | ALOX15 (0.62) | SMN1; SMN2ALOX15PIK3CDSIGMAR1CYP2D6 | |
| SCHEMBL22856157 | 0.85 | HRH2 (0.38) | SMN1; SMN2KEAP1PIK3CDHSD17B10 | |
| SCHEMBL9801269 | 0.85 | KEAP1 (0.47) | SMN1; SMN2KEAP1ALOX15SIGMAR1CYP2D6 | |
| SCHEMBL9801386 | 0.83 | KEAP1 (0.45) | SMN1; SMN2KEAP1ALOX15SIGMAR1CYP2D6 | |
| SCHEMBL19840405 | 0.83 | SMN1; SMN2 (0.48) | SMN1; SMN2KEAP1ALOX15SIGMAR1CYP2D6 | |
| SCHEMBL25461051 | 0.83 | PIK3CD (0.44) | SMN1; SMN2PIK3CDSIGMAR1CYP2D6TP53 | |
| SCHEMBL101501 | 0.81 | KEAP1 (0.67) | SMN1; SMN2KEAP1ALOX15SIGMAR1CYP2D6 | |
| SCHEMBL1616800 | 0.81 | — | — | |
| SCHEMBL21015883 | 0.80 | PIK3CD (0.45) | SMN1; SMN2PIK3CDCYP2D6TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6479482-B2 | 4-(3-((((3-(4-((3-METHYLBUTYL)AMINO)-1-PIPERIDINYL)PROPYL) -AMINO)-CARBONYL)AMINO)PHENYL)-1,4-DIHYDRO-2,6-DIMETHYL-3,5 -PYRIDINEDICARBOXYLIC ACID, DIMETHYL ESTER DIHYDROCHLORIDE, FOR EXAMPLE; ANOREXIANT; NEUROPEPTIDE Y (NPY) | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-12 | — | — | US | disclosed |
| US-20020019384-A1 | Alkylamine derivatives of dihydropyridine NPY antagonists | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-14 | — | — | US | disclosed |
| WO-2001085173-A1 | ALKYLAMINE DERIVATIVES OF DIHYDROPYRIDINE NPY ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020019384-A1 | Alkylamine derivatives of dihydropyridine NPY antagonists | NPY1R, NPY2R, NPY4R | SMN1; SMN2 2849/4885KEAP1 3493/4885ALOX15 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.